Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Anti-Obesity Drugs
share announcement

Anti-Obesity Drugs

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 January 2013) | Viewed by 39554

Special Issue Editor

Dr. Raj Padwal

E-Mail
Guest Editor
Faculty of Medicine & Dentistry, 2J2.00 WC Mackenzie Health Sciences Centre, University of Alberta, 8440 112 Street NW, Edmonton, AB T6G 2B7, USA
Interests: antiobesity drugs; bariatric surgery; bariatric care; hypertension; health outcomes research

Special Issue Information

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antiobesity drug
  • sibutramine
  • orlistat
  • lipase inhibitor
  • cetilistat
  • contrave
  • empatic
  • buproprion
  • zonisamide
  • naltrexone
  • tesofensine
  • endocannabinoid receptor blocker
  • rimonabant
  • incretin
  • beta-3 blocker
  • adrenergic reuptake inhibitor
  • lorcaserin
  • serotonin agonist

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

294 KiB  
Review
Obesity Drug Update: The Lost Decade?
by Fayi Yao and Robert George MacKenzie
Pharmaceuticals 2010, 3(12), 3494-3521; https://doi.org/10.3390/ph3123494 - 24 Nov 2010
Cited by 15 | Viewed by 11378
Abstract
The growing worldwide obesity epidemic and obesity-related disorders present a huge unmet medical need for safe and effective anti-obesity medications. The discovery of leptin in 1994 was rapidly succeeded by a wave of related discoveries leading to the elaboration of a hypothalamic melanocortinergic [...] Read more.
The growing worldwide obesity epidemic and obesity-related disorders present a huge unmet medical need for safe and effective anti-obesity medications. The discovery of leptin in 1994 was rapidly succeeded by a wave of related discoveries leading to the elaboration of a hypothalamic melanocortinergic neuronal circuit regulated by leptin and other central and peripheral signaling molecules to control energy homeostasis. The identification of specific neuronal subtypes along with their unique connections and expression products generated a rich target menu for anti-obesity drug discovery programs. Over the course of the last decade, several new chemical entities aimed at these targets have reached various stages or successfully completed the drug discovery/regulatory process only to be dropped or taken off the market. There are now in fact fewer options for anti-obesity drug therapies in late 2010 than were available in 2000. The challenge to discover safe and effective anti-obesity drugs is alive and well. Full article
(This article belongs to the Special Issue Anti-Obesity Drugs)
►▼ Show Figures

Figure 1

188 KiB  
Review
Combinations of drugs in the Treatment of Obesity
by Bruno Halpern, Eduardo S. L. Oliveira, André M. Faria, Alfredo Halpern, Maria Edna de Melo, Cintia Cercato and Marcio C. Mancini
Pharmaceuticals 2010, 3(8), 2398-2415; https://doi.org/10.3390/ph3082398 - 27 Jul 2010
Cited by 24 | Viewed by 13118
Abstract
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations [...] Read more.
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry. Full article
(This article belongs to the Special Issue Anti-Obesity Drugs)
261 KiB  
Review
Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
by Mª Luisa Isidro and Fernando Cordido
Pharmaceuticals 2010, 3(1), 125-145; https://doi.org/10.3390/ph3010125 - 12 Jan 2010
Cited by 7 | Viewed by 14277
Abstract
Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. [...] Read more.
Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options. Full article
(This article belongs to the Special Issue Anti-Obesity Drugs)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop